- Home
- FDMT vs VOR Comparison
FDMT vs VOR Comparison
Compare FDMT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDMT | VOR |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 515.6M | 755.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FDMT | VOR |
|---|---|---|
| Price | $9.50 | $15.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $31.71 | ★ $45.33 |
| AVG Volume (30 Days) | 783.4K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $2.89 | $0.13 |
| 52 Week High | $12.34 | $49.95 |
Technical Indicators
Market Signals| Indicator | FDMT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 52.12 |
| Support Level | $8.41 | $11.38 |
| Resistance Level | $9.78 | $16.88 |
| Average True Range (ATR) | 0.64 | 1.62 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 44.44 | 40.99 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.